Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

332 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of granulocyte-macrophage colony stimulating factor produced in Chinese hamster ovary cells (regramostim), Escherichia coli (molgramostim) and yeast (sargramostim) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy.
Hussein AM, Ross M, Vredenburgh J, Meisenberg B, Hars V, Gilbert C, Petros WP, Coniglio D, Kurtzberg J, Rubin P, et al. Hussein AM, et al. Eur J Haematol. 1995 Nov;55(5):348-56. doi: 10.1111/j.1600-0609.1995.tb00713.x. Eur J Haematol. 1995. PMID: 7493686 Clinical Trial.
Effects of granulocyte-macrophage colony stimulating factor produced in Chinese hamster ovary cells (regramostim), Escherichia coli (molgramostim) and yeast (sargramostim) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy.
Hussein AM, Ross M, Vredenburgh J, Meisenberg B, Hars V, Gilbert C, Petros WP, Coniglio D, Kurtzberg J, Rubin P, et al. Hussein AM, et al. Eur J Haematol. 1995 May;54(5):281-7. doi: 10.1111/j.1600-0609.1995.tb00687.x. Eur J Haematol. 1995. PMID: 7781752 Corrected and republished. Clinical Trial.
A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies.
Hussein AM, Petros WP, Ross M, Vredenburgh JJ, Affrontil ML, Jones RB, Shpall EJ, Rubin P, Elkordy M, Gilbert C, Gupton C, Egorin MJ, Soper J, Berchuck A, Clarke-Person D, Berry DA, Peters WP. Hussein AM, et al. Cancer Chemother Pharmacol. 1996;37(6):561-8. doi: 10.1007/s002800050429. Cancer Chemother Pharmacol. 1996. PMID: 8612310 Clinical Trial.
Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone.
Vredenburgh JJ, Coniglio D, Broadwater G, Jones RB, Ross M, Shpall EJ, Hussein A, Rizzieri D, Marks LB, Gilbert C, Affronti ML, Moore S, McDonald C, Petros WP, Peters WP. Vredenburgh JJ, et al. Biol Blood Marrow Transplant. 2006 Feb;12(2):195-203. doi: 10.1016/j.bbmt.2005.10.009. Biol Blood Marrow Transplant. 2006. PMID: 16443517 Free article. Clinical Trial.
Characteristics and outcomes of COVID-19 patients admitted to hospital with and without respiratory symptoms.
Citarella BW, Kartsonaki C, Ibáñez-Prada ED, Gonçalves BP, Baruch J, Escher M, Pritchard MG, Wei J, Philippy F, Dagens A, Hall M, Lee J, Kutsogiannis DJ, Wils EJ, Fernandes MA, Tirupakuzhi Vijayaraghavan BK, Panda PK, Martin-Loeches I, Ohshimo S, Fatoni AZ, Horby P, Dunning J, Rello J, Merson L, Rojek A, Vaillant M, Olliaro P, Reyes LF; ISARIC Clinical Characterisation Group. Citarella BW, et al. Heliyon. 2024 May 4;10(10):e29591. doi: 10.1016/j.heliyon.2024.e29591. eCollection 2024 May 30. Heliyon. 2024. PMID: 38779000 Free PMC article.
332 results